Pharmacokinetics of depot medroxyprogesterone acetate contraception.
about
Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmissionResearch gaps in defining the biological link between HIV risk and hormonal contraceptionMedroxyprogesterone acetate enhances in vivo and in vitro antibody productionA randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.Effects of depot-medroxyprogesterone acetate on the immune microenvironment of the human cervix and endometrium: implications for HIV susceptibility.The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor.Progesterone-based intrauterine device use is associated with a thinner apical layer of the human ectocervical epithelium and a lower ZO-1 mRNA expression.Molecular mechanisms linking high dose medroxyprogesterone with HIV-1 risk.Medroxyprogesterone acetate increases HIV-1 infection of unstimulated peripheral blood mononuclear cells in vitro.Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study.Medroxyprogesterone acetate impairs human dendritic cell activation and function.Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of ageDendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infectionHigh dose of green tea infusion normalized spiral artery density in rats treated with the depot-medroxyprogesterone acetate.Role of the short isoform of the progesterone receptor in breast cancer cell invasiveness at estrogen and progesterone levels in the pre- and post-menopausal ranges.Medroxyprogesterone acetate inhibits CD8+ T cell viral-specific effector function and induces herpes simplex virus type 1 reactivation.Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.Hormonal contraceptive use and risk of HIV-1 disease progressionComparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women.6β-Methyl-3,20-dioxopregn-4-en-17-yl acetate.Discordance between Self-Reported Contraceptive Use and Detection of Exogenous Hormones among Malawian Women Enrolling in a Randomized Clinical Trial.Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.
P2860
Q21090622-529AC49A-7FBE-4758-AA9D-008D6A38D554Q27002559-76F62228-167F-460F-8F23-DB80C342CFCFQ28360458-930C9A67-D617-456F-928B-03E543FDC07FQ33763511-BC1C656F-1874-418B-B685-8362739F30CFQ33864122-9B66CF7A-BBCD-4261-AFA0-ED1EEDDA9774Q33870365-65809A09-ADCE-424C-AA80-390B09653F90Q34712821-D5A6F1A9-4A07-448E-BE9B-A45C8C92D4C7Q35172396-192F5163-CD1E-4F2C-B457-9FC4CEACA387Q35208283-E8BA03E8-D34F-4E69-9392-FAE8C7A0142EQ35676330-5D6DFF56-DC00-4647-A55E-00FA752AA257Q35741533-781A3747-1560-42C7-B02B-FB258531830AQ35784803-3520248C-AF31-4053-964A-9A4F6E80FE04Q35817142-66C2AFB5-FBD1-45C6-8E18-922A6A4FA1E2Q35894901-0F767CAD-FFA0-4EAD-90CB-6B0E20BCF7B5Q36252465-A957D375-807E-4D7D-B237-AA4A9F435CA1Q36271139-F36F6957-43FA-416F-8E5C-C5682B4ADE67Q36545100-9727CCB4-854F-447E-A76E-96F13B2EE2EBQ36909530-4497ED88-A3C1-4858-BFFE-061ED8FF3802Q36973336-F07963BD-E180-482E-B11A-2214AF24094EQ37088950-5966C4FC-B38D-41F7-AE7B-C1762A0F3AE5Q40248406-5FF30040-7BDA-4231-A01D-91615D8D5910Q42147210-0DDFA2F5-100E-4F49-98F6-D3287F395ABDQ46749807-1FFB6401-B922-4FE4-8105-DE3ECD9161A0Q47151161-F20E9762-A504-43D2-BB88-8BE09C8F7128Q47198102-D86B7A6C-8541-4980-86F6-95BE43C9C91AQ49838895-BD68CB2F-90C0-4679-8F47-BC368BFBA3ACQ55514511-923BD00F-92BF-48B6-87AF-F49B51E46451
P2860
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
name
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@ast
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@en
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@nl
type
label
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@ast
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@en
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@nl
prefLabel
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@ast
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@en
Pharmacokinetics of depot medroxyprogesterone acetate contraception.
@nl
P1476
Pharmacokinetics of depot medroxyprogesterone acetate contraception
@en
P2093
Mishell DR Jr
P304
P433
P577
1996-05-01T00:00:00Z